Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00912_nanopub.RA1lAg0y4kh68yAGKEGIBvvhuL73JmVqMzYkd42RfenKQ#assertion>. }
Showing items 1 to 28 of
28
with 100 items per page.
- drugbank:DB00912 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00912 label "Repaglinide [drugbank:DB00912]" assertion.
- drugbank:DB00912 seeAlso prandin.htm assertion.
- drugbank:DB00912 seeAlso pra1343.shtml assertion.
- drugbank:DB00912 seeAlso repaglinide.html assertion.
- drugbank:DB00912 seeAlso DB00912 assertion.
- drugbank:DB00912 description "Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine." assertion.
- drugbank:DB00912 identifier "drugbank:DB00912" assertion.
- drugbank:DB00912 title "Repaglinide" assertion.
- drugbank:DB00912 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46508150 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-pubchemcompound pubchem.compound:65981 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-chemspider chemspider:59377 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-cas cas:135062-02-1 assertion.
- drugbank:DB00912 drugbank_vocabulary:drugbank-id "APRD00439" assertion.
- drugbank:DB00912 drugbank_vocabulary:drugbank-id "DB00912" assertion.
- drugbank:DB00912 bio2rdf_vocabulary:x-identifiers.org DB00912 assertion.
- drugbank:DB00912 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00912" assertion.
- drugbank:DB00912 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00912 bio2rdf_vocabulary:identifier "DB00912" assertion.
- drugbank:DB00912 drugbank_vocabulary:x-wikipedia wikipedia:Repaglinide assertion.
- drugbank:DB00912 drugbank_vocabulary:x-pharmgkb pharmgkb:PA451234 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-kegg kegg:D00594 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-kegg kegg:C07670 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-dpd dpd:2239925 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-atc atc:A10BX02 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-ahfs ahfs:68:20.16 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-bindingdb bindingdb:50153520 assertion.
- drugbank:DB00912 drugbank_vocabulary:x-ndc ndc:35356-303-01 assertion.